Loxo Oncology is innovating the development of highly selective medicines for patients with genetically defined cancers. Learn More.
Location: United States, Connecticut, Stamford
Employees: 201-500
Total raised: $57M
Founded date: 2013
Investors 3
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Aisling Ca... | aislingcap... |
| - | Aquilo Cap... | aquilocapi... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 06.05.2014 | Series B | $24M | - |
| 03.10.2013 | Series A | $33M | - |
Mentions in press and media 18
| Date | Title | Description |
| 07.10.2021 | Eli Lilly and : Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics | INDIANAPOLIS, Oct. 7, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that preclinical characterization data for two new agents, LOXO-783 and LOXO-435, will... |
| 20.01.2019 | The inside story of Eli Lilly's 18-day race to secure an $8 billion deal in time for the 'Super Bowl' of healthcare | Close up of cancer cells. American Cancer Society/Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Drugmaker Eli Lilly & Co. first approached the biotech Loxo Oncology abo... |
| 17.01.2019 | The inside story of Eli Lilly's 18-day race to secure an $8 billion deal for a drugmaker that's pioneering a new treatment for cancer | American Cancer Society/Getty Images Close up of cancer cells. Advertisement Drugmaker Eli Lilly & Co. first approached the biotech Loxo Oncology about an acquisition on Dec. 20, just weeks before it wanted to announce the agreement at ... |
| 07.01.2019 | Term Sheet — Monday, January 7 | HOPING FOR A MARKET DIP Happy New Year, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop — In December, Term Sheet published readers’ business-related predictions for 2019. Many of you predicted a recession... |
| 02.12.2018 | FDA approval puts Loxo, Bayer’s Vitrakvi on the rails to value-based care | On the one hand, the fusions’ rarity makes it more challenging to find patients who qualify for the drug. But on the other hand, it makes Vitrakvi something of a poster child for the concept of value-based care. In a nutshell, value-based c... |
| 26.11.2018 | Loxo, Bayer’s Vitrakvi wins FDA approval. Now comes the hard part: finding patients | NTRK fusions occur in a wide variety of solid tumors and help to drive their growth, but their occurrence varies considerably from one cancer histology to the next. Yet, among patients with the fusion, about 80 percent responded to treatmen... |
| 03.06.2018 | Updated ASCO data from Loxo study show more patients responding | The data showed 77 percent of 49 patients with RET fusions responding, including 74 percent confirmed responses, according to a press release Saturday. Meanwhile, 45 percent of 29 patients with RET mutation-positive medullary thyroid cancer... |
| 02.06.2018 | Spurring move to personalized therapies, Loxo elbows its way back into the ASCO spotlight with 2nd tissue-agnostic cancer drug success | CHICAGO — With their lead drug — and ASCO17 star — larotrectinib making the final run-up to a widely expected approval in November, Loxo Oncology $LOXO is back at the big cancer conference this year with its next drug in th... |
| 17.05.2018 | The top winners and losers on ASCO abstract night: Loxo, Blueprint, Jounce, Merck KGaA and more | Let the jousting begin. The big abstract drop ahead of ASCO — the annual Olympics of cancer R&D — provided some early, quick snapshots that helped drive stocks up or down, or simply provided a chance to tout some potent... |
| 03.06.2017 | Loxo takes center stage at ASCO with its groundbreaking shot at a biomarker-based cancer drug approval | CHICAGO — Loxo Oncology made it into the ASCO showcase over the weekend, boasting of a small but growing number of cases where children and adults with TRK fusion cancer responded to their lead drug, larotrectinib (LOXO-10... |
Show more